The role of the renin-angiotensin system has been investigated by overexpression or inactivation of its different genes in animals. However, there is no data concerning the effect of the constitutive activation of any component of the system. A knockin mouse model has been constructed with a gain-of-function mutant of the Ang II receptor, type 1A (AT 1A ), associating a constitutively activating mutation (N111S) with a C-terminal deletion, which impairs receptor internalization and desensitization. In vivo consequences of this mutant receptor expression in homozygous mice recapitulate its in vitro characteristics: the pressor response is more sensitive to Ang II and longer lasting. These mice present with a moderate (~20 mmHg) and stable increase in BP. They also develop early and progressive renal fibrosis and cardiac fibrosis and diastolic dysfunction. However, there was no overt cardiac hypertrophy. The hormonal parameters (lowrenin and inappropriately normal aldosterone productions) mimic those of low-renin human hypertension. This new model reveals that a constitutive activation of AT 1A leads to cardiac and renal fibrosis in spite of a modest effect on BP and will be useful for investigating the role of Ang II in target organs in a model similar to some forms of human hypertension.
Introduction
The Ang II receptor, type 1 (AT 1 ), is a G protein-coupled receptor (GPCR) that transduces the main physiological actions of the renin-angiotensin system (RAS) in target cells. The major signaling events following agonist binding to this receptor are activation of phospholipase C via a Gq protein, mobilization of the calcium intracellular stores, and activation of protein kinase C. MAP kinase and Jak/STAT pathways are also activated and may participate in the hypertrophic actions of Ang II (1) . There are 2 AT 1 subtypes in rodents, AT 1A and AT 1B (2, 3) ; the tissue distribution of the 2 subtypes (4) and knockout experiments in mice (5-7) indicate that cardiovascular, renal, and adrenal actions of Ang II are mainly mediated by AT 1A . The unambiguous role of AT 1 in controlling BP is evidenced in numerous animal models. For example, the knockout of AT 1A in mouse reduces BP (5, 6) , and its overexpression by gene duplication increases BP in female mice (8) . This role contrasts with the absence of clear involvement of renin angiotensin genes in genetic forms of human hypertension (9) .
The concept of constitutive activation is an important breakthrough in the understanding of GPCR molecular functions: point mutations stabilize the receptor in an active conformation independent of ligand, resulting in a permanent activation of the signaling pathways (10) . Several human genetic diseases appear to be consequences of such GPCR gain-of-function mutant expression (11, 12) . Therefore, it was logical to investigate whether cases of human hypertension are associated with such activating mutations of AT 1 . However, no mutation of AT 1 coding sequence had previously been identified in hypertension or, more particularly, in primary hyperaldosteronism (13, 14) . This absence of clearly identified gain-of-function mutations of AT 1 in humans prompted us to map the mutations of the rat AT 1A that cause constitutive activity by screening a randomly mutated library of the receptor with a functional assay (15) . The next step was to develop an animal model expressing a gain-of-function mutant of AT 1 , to answer 2 questions: (a) What are the effects of a permanent activation of this GPCR on BP? (b) If BP increases, what are the characteristics of this new experimental hypertension in terms of severity, course, target organ damage, and how or when the RAS is reset?
The choice of the mutation(s) was directed by the initial in vitro characterization of these constitutively activated mutants. All these AT 1A mutants are slightly constitutively active when compared with the WT receptor but are far from being fully active. Therefore, they can still be activated by agonists. Among the different constitutively active mutations, one of the most active is the N111S mutation. This N111S mutation, as other constitutively active mutations, induces constitutive internalization, resulting in intracellular sequestration of most receptor molecules (16) .
For these reasons, we expected a mild phenotype and added to the N111S mutation a C-terminal deletion of the receptor, which impairs phosphorylation and internalization, abolishing desensitization and inducing hyper-reactivity to Ang II (17) . As expected, cellular expression of AT 1A bearing both these gain-of-function mutations revealed additivity of constitutive activity and hyperreactivity to Ang II in vitro (18) .
Here, we describe in vivo expression of this gain-of-function mutant in a knockin mouse model and the main characteristics of the phenotype. The constitutive activation of this receptor, associated with impaired internalization, produces a new model of mouse hypertension characterized by normal aldosterone production in the presence of very low plasma renin and the existence of cardiac, vascular, and renal fibrosis.
Results

Generation of mice expressing the AT 1A N111S/Δ329 mutant
Homozygous mice expressing the gain-of-function AT 1A mutant were generated as described in Figure 1 . Specific expression of the AT 1A N111S/Δ329 mutation (AT 1A MUT), but not AT 1A WT, was identified by RT-PCR in the major AT 1A -expressing tissues (liver, heart, kidney, adrenal gland, and aorta) of homozygous mutant mice (data not shown). No difference in expression of AT 1A , AT 1B , or AT 2 was observed when RNA from those Ang II target tissues of WT and mutant mice were compared using quantitative RT-PCR ( Figure 2 ). Similar results were obtained by in situ hybridization using specific probes for the 3 Ang II receptors (data not shown).
All the phenotypic comparisons were made between homozygous mutant mice and WT littermates at the same age. The mutant mice had significantly lower body weights (10% to 20% lower), first observed in young animals (1 to 3 months old) and persisting throughout the life of the mouse without any clear sex difference (Table 1 ). An interesting and unexpected phenotypic trait was the higher concentration of red blood cells (17% higher) and hemoglobin (12% higher) and an increased hematocrit (12% higher), in mutant compared with control mice. These differences seem to correspond to true polyglobulia rather than to hemoconcentration because total plasma protein concentration and osmolality were unaffected (Table 2) .
Gain-of-function features of AT 1A MUT in mice
In vitro characterization in tissues and isolated hepatocytes. The constitutive activity of AT 1A MUT was first investigated by comparing the phosphorylated state of signaling molecules such as STAT1, STAT3, and ERK1/2 in tissues (liver, heart, and kidney) of AT 1A WT
Figure 1
Targeted knockin of the Agtr1a gene by homologous recombination into ES cells and mouse. (A) Schematic representation of the targeting vector and partial restriction map of the Agtr1a gene locus before and after homologous recombination. The top line shows the structure of AT1AWT locus containing exon 3 of the gene with coding sequence (black box) and the 5′ and 3′ untranslated sequences (gray boxes). Exon 3 is flanked by 3 kb of intron 2 (upstream) and 2 kb of noncoding sequence (downstream). The targeting construct containing AT1AMUT and a hygromycin cassette (hygro) was used to replace the WT BamHI (B) KpnI (K) fragment within AT1A locus (middle line). The lower line shows the targeted AT1A locus with the internal probe (probe 1) and 3′ external probe (probe 2) used for Southern blot analysis. (B) Southern blot analysis of targeted ES cell DNA using internal probe 1 with SpeI digestion (left) and using probe 2 with SacI digestion (right). C, control (targeting construct). -/-, WT cells; +/-, heterozygous recombinant cells. (C) Southern blot analysis of tail DNA samples from F2 offspring (generated by crossing heterozygous mice from the first generation [F1 mice]) digested with SacI and probed with the 3′ external probe (probe 2). -/-, WT mice; +/-, heterozygous transgenic mice; +/+, homozygous transgenic mice; S, SpeI; B, BamHI; G, BglII; X, XbaI; A, SacI; K, KpnI; N, NotI; E, EcoRI.
and AT 1A MUT mice. Given the modest constitutive activity of the N111S/Δ329 mutant, it was not surprising to observe only modest changes in basal phosphorylations. In the liver, STAT1 increased 36% (P = NS) and STAT3 increased 63% (P < 0.05), but ERK1/2 phosphorylation did not increase, in AT 1A MUT mice ( Figure 3A) . In heart and kidney, no change was observed in STAT1 or STAT3 phosphorylation, whereas ERK1/2 basal phosphorylation was slightly (35% to 45%) but significantly increased in AT 1A MUT mice (data not shown). In order to gain more insight into the functional properties of AT 1A WT and AT 1A MUT receptors, their pharmacology and signaling were investigated in freshly isolated hepatocytes (Table 3 and Figure 3 ). The AT 1A MUT and AT 1A WT receptors presented similar expression levels and a similar affinity for Ang II in the liver. The pharmacological profiles of the AT 1A MUT and AT 1A WT receptors in the liver were compared: there were no differences in affinity for the peptide analog [Sar1-Ile8] Ang II, but AT 1A MUT had a lower affinity for the nonpeptide AT 1 antagonist losartan and a higher affinity for CGP42112A (a pseudopeptide agonist for AT 2 ) and Ang IV (angiotensins 3-8) (Table 3) . Ang IV is a full agonist for these constitutively activated receptors, as indicated by the strong and dosedependent stimulation of ERK1/2 phosphorylation ( Figure 3C ). This constitutive activation of AT 1A MUT in hepatocytes is associated with its hyperreactivity and hypersensitivity to Ang II: compared with the AT 1A WT receptor, the maximal ERK1/2 phosphorylation in the AT 1A MUT receptor increased by 2-fold and sensitivity of the response to Ang II was better (50% effective concentration [EC 50 ] = 0.39 ± 0.16 nM, AT 1A MUT; 2.10 ± 0.55 nM, AT 1A WT; P < 0.05) (Figure 3B) . This pharmacological and signaling profile is similar to that reported for the same mutant in transfected cells (18) and reproduces some of the characteristics of constitutively activated AT 1 , which bind inverse agonists with at least 100-fold lower affinity compared with AT 1A WT receptors (19) . Conversely, CGP42112A and Ang IV have a much better affinity and become full agonists for AT 1A MUT (15) .
In vivo vascular responsiveness to Ang II. The BP response to Ang II was analyzed by invasive methods on anesthetized 5-monthold animals ( Figure 4 ). As expected, Ang II increased the BP of AT 1A WT animals in a dose-dependent manner, with a sharp initial peak after injection followed by a progressive return to basal BP within approximately 3 minutes ( Figure 4A ). Interestingly, in AT 1A MUT mice, the initial BP rise was followed by a plateau that lasted for at least 30 minutes, without any return to the basal level ( Figure 4A ). The cumulative doses of Ang II (0.0001-30 μg/kg) raised the systolic BP measured 10 minutes after the last injection by 60 mmHg in AT 1A MUT mice, whereas it increased only 25 mmHg in AT 1A WT animals. The BP response to Ang II as assessed from the area under the curve in AT 1A MUT mice (ED 50 = 0.07 ± 0.16 μg/kg) was considerably more sensitive than that in the AT 1A WT mice (ED 50 = 0.63 ± 0.23 mg/kg; P < 0.05) (Figure 4B ). These data suggest strongly that the transduction of the BP response to Ang II via the AT 1A MUT receptor is more sensitive compared with AT 1A WT and that this response is not desensitized. This nondesensitized BP response is independent of kidney AT 1A , at least in acute conditions, since binephrectomy does not modify the sustained BP response to Ang II (data not shown). In addition, the specificity of the sustained BP response via AT 1A MUT is assessed by the clear agonist effect of CGP42112A, which is ineffective in AT 1A WT mice ( Figure 4C ) and by a similar BP response to epinephrine in the 2 groups of mice (data not shown).
AT 1A MUT mice are hypertensive Tail-cuff measurements of systolic BP ( Figure 5A ) revealed a BP increase in AT 1A MUT mice as young as 5 weeks old. This BP 
Figure 2
Quantitative RT-PCR of the Ang II receptors in target tissues. RNA from liver, kidney, heart, adrenal gland, and aorta were retrotranscribed and amplified for AT1A (A), AT1B (B), and AT2 (C) mRNAs using the LightCycler technology in AT1AWT (white bars) and AT1AMUT (black bars) mice. Results are expressed in arbitrary units relative to the expression of cyclophilin gene in the same tissues. ND, not detectable.
elevation was moderate (~20 mmHg) and persisted with similar severity throughout life without progressive aggravation. It was more severe in male mice (23-35 mmHg) than in female mice (11-17 mmHg) mice. Malignant hypertension was not detected at any time, despite careful testing for symptoms. This permanent hypertension was confirmed by invasive measurements of systolic (122 ± 4 mmHg in AT 1A MUT mice compared with 95 ± 6 mmHg in AT 1A WT mice; P < 0.01) and diastolic BP values (92 ± 6 mmHg in AT 1A MUT mice compared with 69 ± 5 mmHg in AT 1A WT mice; P < 0.01) in anesthetized animals. Pharmacological reduction of BP by AT 1 blockers (ARBs) was investigated, despite the fact that ARBs (inverse agonists) present altered affinities for AT 1A constitutively activated mutants (19) . According to Le et al. (19) , candesartan has the highest ARB affinity for the N111S mutant (K d = 2.49 ± 0.29 nM compared with 0.27 ± 0.07 for the AT 1A WT receptor) and losartan has the lowest affinity for the mutant receptor (K I = 548 ± 140 nM). Candesartan treatment (10 mg/kg/d) during 25 days reduced (by approximately 30 mmHg) BP of AT 1A MUT animals to normal levels ( Figure 5B ). However, losartan treatment (30 mg/kg/d or 150 mg/kg/d) for 2 weeks significantly reduced the BP of AT 1A WT animals (by 11 mmHg and 20 mmHg for the respective doses) but had no effect on AT 1A MUT animals (data not shown).
AT 1A MUT mice have high BP with low-renin hypertension and relative hyperaldosteronism
The consequences for the RAS of the expression of this AT 1A MUT in mice were analyzed. Plasma renin concentration (PRC) was considerably lower in mutant mice than in AT 1A WT mice ( Figure 6A) . This low PRC level was presumably the consequence of a large decrease in the production of renin by the juxtaglomerular apparatus in the kidney. This was confirmed by in situ hybridization for renin mRNA in these structures for both adult (5-month) and neonate (2-day) mice (Figure 6, C and D). Plasma renin substrate was unaffected (data not shown). These low-renin concentrations in AT 1A MUT mice resulted in a 50% decrease of immunoreactive angiotensin plasma concentrations ( Figure 6B ). Further studies are needed to identify whether this decrease involves Ang II, Ang III, and Ang IV equally, as they are all measured by this assay. The low-renin production contrasts with normal concentrations of aldosterone in both plasma and urine from AT 1A MUT animals ( Figure  6E ). No morphological abnormality was observed in the adrenal cortex of AT 1A MUT animals. There was no hypertrophy of the zona glomerulosa, and the aldosterone synthase gene (CYP11B2) was expressed at a normal level, as assessed by in situ hybridization (data not shown). A 10-fold increase in plasma aldosterone/renin ratio was the main hallmark of the endocrine profile of this new experimental hypertension ( Figure 6F ).
Renal consequences of hypertension and RAS alterations
We investigated the pathophysiological consequences of the expression of AT 1A MUT on kidney structure and functions: urinary samples were collected from 6-to 7-month-old animals in metabolic cages, plasma was sampled, and renal morphology was analyzed.
The 24-hour diuresis of AT 1A MUT animals was lower than AT 1A WT (Table 1) . This was associated with a higher urinary osmolality but a normal plasma osmolality (Table 2) .
After correction for body weight and 24-hour diuresis, creatinine excretion in mutant mice was significantly lower than in AT 1A WT mice ( Figure 7A ), whereas plasma creatinine concentration was normal and plasma urea was slightly but significantly higher (Table 2 ). There were no obvious tubular pathology or major plasma or urinary electrolyte abnormalities ( Figure 7B and Table 2 ).
These moderate functional changes were associated with periglomerular and perivascular fibrosis without major changes in glomerular or tubular morphology ( Figure 7C ). Confirmation of this fibrosis was investigated by measuring expression of 2 molecular markers, collagen αI and plasminogen activator inhibitor type 1 (PAI1), using quantitative RT-PCR ( Figure 7D ). Despite a 3-fold increase in these markers in AT 1A MUT mice, this difference was not significant due to an important variability of the markers in AT 1A MUT mice. The origin of this variability is not linked to age but may be linked to gender, and it should be further investigated. A moderate but significant hypertrophy of the small renal arteries was also observed ( Figure 8A ).
AT 1A MUT mice present with progressive cardiac fibrosis Morphological and echocardiographic investigations of the cardiac structure and function in 5-and 12-month-old AT 1A MUT and AT 1A WT mice were performed. The AT 1A MUT animals did not present any major cardiac hypertrophy. The heart weight/body weight ratio was unchanged in 5-month-old animals and in 12-monthold females ( Figure 8B ). However, the ratio was slightly but significantly higher in 12-month-old AT 1A MUT males compared with AT 1A WT males (data not shown). These changes in heart weight were not associated with any increase in atrial natriuretic factor (ANF) expression, but a clear (>3-fold) and significant increase of brain natriuretic peptide (BNP) expression was observed in the heart of AT 1A MUT mice ( Figure 8C ).
The absence of obvious cardiac hypertrophy in mutant mice was confirmed by echocardiography. Left ventricle mass was the same in mutant and AT 1A WT mice at both 5 and 12 months of age (Table 4) . Echocardiography detected a mild, late decrease in contractility in AT 1A MUT mice as assessed by tissue Doppler imaging (Table 4) ; the ejection fraction was not significantly lower, but there was mild left ventricle remodeling, as shown by the higher left ventricle end-diastolic diameter relative to body weight in AT 1A MUT mice. However, a clear, early alteration in diastolic left ventricle function was detected (Table 4 ) with variables associated with myocardial relaxation being abnormal. In 12-month-old mice the abnormal diastolic function was accompanied by high left ventricle filing pressure, as depicted by the ratio of the maximal blood velocity of early left ventricle inflow to the maximal velocity of early diastolic motion of the mitral annulus, with relatively conserved systolic function, the hallmark of diastolic heart failure.
Morphological analysis of serial heart slices unambiguously showed the presence of a cardiac fibrosis in AT 1A MUT mice ( Figure  8D ), without cardiomyocyte hypertrophy or inflammation. This fibrosis predominated in pericoronary area but was also observed in interstitial spaces. It was not detected until 3 months of age, but it became apparent in 4-month-old mutant mice and progressed with time to become evident at 1 year without any sex preference. This cardiac fibrosis was confirmed at the molecular level, with an important (>3-fold) and significant increase of collagen αI expression, whereas only a limited and nonsignificant increase of PAI1 expression was observed in 5-month-old AT 1A MUT mice ( Figure 8E ).
Discussion
Expression of a gain-of-function AT 1A MUT at its physiological sites in the mouse results in a permanent, nonmalignant form of hypertension characterized by a normal aldosterone level but low-renin secretion. This permanent hypertension is unusual because of its early development, the absence of aggravation during mouse life, its moderate severity, and its predominance in males. The roles of various genes of the RAS that are potentially involved in the control of BP (renin, angiotensinogen, angiotensin-converting enzyme, and AT 1 genes) has been extensively investigated both by overexpression and by inactivation in mice and rats (20) (21) (22) (23) (24) (25) (26) . Inactivation of the Agtr1a gene (27) but not the Agtr1b (7) or the Agtr2 (28, 29) genes, causes a BP decrease, and the duplication of Agtr1a gene results in a moderate increase of BP in female mice (8) . Sex differences in BP changes were also observed in Ren1d KO (21) and Ace KO (20) female mice, which had decreased BP, but these apparently discordant differences were never explored further. These data confirm that quantitative alterations of RAS gene expression modulate BP. However, there are no data about the effect of constitutive activation of any of the RAS components on BP or cardiovascular or renal functions.
In the present study, the observed phenotype is a result of qualitative, not quantitative, functional alterations of AT 1A . Indeed, The first mutation is an N111S point mutation that induces partial constitutive activation of AT 1A . Constitutive activation of AT 1A is confirmed in vivo in AT 1A MUT mice by several experimental data: (a) pharmacological and signaling profiles of AT 1A that are similar in hepatocytes from AT 1A MUT mice and cells transfected with different constitutively active AT 1A mutants (15, 18) ; (b) increase of STAT1, STAT3, and ERK1/2 basal phosphorylation in some Ang II target tissues; (c) correction of hypertension with the inverse agonist candesartan, which has high affinity for AT 1A MUT (19); (d) and full agonist effect of CGP42112A on AT 1A MUT mouse BP, as previously shown in vitro on constitutively active mutants (15) .
Altogether, these results sustain the hypothesis that, at least in part, the mouse phenotype is a result of constitutive activation of the receptor. This animal model, in addition to cellular models expressing the AT 1A MUT receptor, could thus help in the evaluation of other new and more potent agonists or antagonists. The AT 1A MUT mouse is the first animal model expressing a constitutively active GPCR in a physiological context. Previous reports have described overexpression of constitutively active mutants of the α1B and β2 adrenergic receptors in the heart (30, 31) and the parathyroid hormone receptor in the growth plate (11) . Surprisingly the gain-of-function phenotype was often replaced by a lossof-function phenotype as a result of cellular sequestration or toxicity of the GPCR mutant. To avoid constitutive internalization and desensitization of the constitutively active AT 1A previously described in cellular models (16), we added a second mutation, i.e., a C-terminal deletion (Δ329). In absence of the C-terminal tail, the receptor cannot be phosphorylated, does not interact with β-arrestins, is not internalized, and is not desensitized (17) . The in vivo consequences of this deletion confirmed the observations in cellular systems. The hypertensive response to Ang II was amplified and long lasting in AT 1A MUT animals. This sustained response to Ang II strongly suggests that the mutant receptor is not turned off after Ang II activation. Other reports indicated the possibility of desensitization alterations of GPCRs such as β-adrenergic receptors in heart failure (32), but to our knowledge the present knockin (AT 1A MUT) is the first animal model in which the physiological consequences of the expression of a non-desensitized GPCR could be investigated.
Hypertension of AT 1A MUT mice is associated with low plasma renin levels, a consequence of a decreased renal renin synthesis, as shown by in situ hybridization and low plasma angiotensin levels. In contrast, there is no alteration in aldosterone synthesis, plasma and urinary aldosterone are normal, there are no major changes in electrolyte balance, and notably, there is normal kalemia. Such a discrepancy between renin production and aldosterone production has already been observed in Agtr1a KO mice (high renin and normal aldosterone levels) (33) . A possible explanation for the lack of aldosterone overproduction is the particular status of the zona
Figure 6
Renin-angiotensin-aldosterone system parameters. Plasma renin (A), plasma immunoreactive angiotensin (B), and plasma aldosterone (E) concentrations were determined in AT1AWT mice (white bars) and AT1AMUT mice (black bars). (C) Representative in situ hybridization detection of renin expression in kidney sections from AT1AWT and AT1AMUT adult (C) and neonate (D) animals. The juxtaglomerular apparatus is indicated by arrows. Relative hyperaldosteronism was also evaluated by computing the aldosterone/renin ratio (F). *P < 0.05, ***P < 0.001 compared with AT1AWT. glomerulosa in the mouse adrenal cortex in terms of AT 1 expression, since these cells express equal amounts of AT 1A and AT 1B (4) . Therefore, the production of aldosterone is stimulated by the gainof-function AT 1A but is no longer stimulated via AT 1B because of the decrease in circulating Ang II. The result may be a normal aldosterone production, which is nevertheless inappropriate in view of the low-renin values. Alternatively the normal levels of aldosterone could be the result of other RAS-independent factors regulating aldosterone production. This phenotype, together with the hypersensitivity to Ang II infusion, resembles that classically described in primary hyperaldosteronism, in which there is an abnormal renin/aldosterone ratio (34) . We and others have tried unsuccessfully to identify mutations of the Agtr1 gene in aldosterone-producing adenomas (13, 14) , but other forms of low-renin hypertension with or without hyperaldosteronism should be screened.
This AT 1A MUT mouse is an interesting model in which to investigate the renal modifications that follow receptor activation. Such a model may help to define the roles of renal and extrarenal tissues in the development of hypertension. A recent, elegant study by Crowley et al. demonstrated the additive roles of kidney and systemic tissues in BP regulation using a renal cross-transplantation strategy (35) . Similar experiments in AT 1A MUT mice would further define these distinct roles in the regulation of BP via the RAS.
Ang II regulates water balance by both central (dipsogenic effects) and renal (vasopressin secretion, urine concentration) actions. The AT 1A MUT mice had lower diuresis and higher urinary osmolality than controls. The opposite (higher diuresis and lower urinary osmolality) has been observed in AT 1A KO mice (36) . Normal plasma natremia in AT 1A MUT mice excludes the presence of an inappropriate vasopressin secretion, and there is no clear dipsogenic effect of the mutant receptor. This suggests that AT 1A MUT acts on water homeostasis mostly by urine concentration in the kidney (33) .
Ang II also controls the sodium balance by regulating renal hemodynamics and stimulating sodium reabsorption in the renal tubules directly or indirectly via aldosterone secretion. No major modification of the sodium balance was detected in AT 1A MUT mice on a normal sodium diet, but further studies involving various sodium diets and water intakes will be necessary to precise the link between sodium balance and hypertension in these animals.
The consequences of AT 1A activation on end organ damage were investigated in AT 1A MUT mice. Cardiovascular hypertrophy, as assessed by morphological and echographical analyses, is moderate and late in mutant mice. It is observed especially in old male mice, suggesting a predominant role of hypertension in its development. Therefore, AT 1A activation in the heart seems to have little physiological involvement in cardiomyocyte hypertrophy. This result strongly contrasts with other experimental data, showing that AT 1A -specific overexpression in the heart of transgenic mice (37) (38) (39) induces massive cardiac hypertrophy with conduction defects but without hypertension. However, part of this phenotype may be the result of a nonspecific effect of AT 1A overexpression in cardiomyocytes.
The major cardiovascular modification in AT 1A MUT mice is fibrosis. This fibrosis appears in early adulthood (4 months), progresses throughout the life of the mouse, is predominantly perivascular but is also interstitial, and is associated with an increased expression of collagen αI. Cardiac fibrosis parallels the functional cardiac alterations that occur early in AT 1A MUT mice (5 months of age), and this phenotype is similar to that observed in human cardiac fibrotic diseases, i.e., alteration of diastolic function, with subsequent evolution toward diastolic heart failure. The results in AT 1A MUT mice point to a direct action of Ang II via AT 1A on extracellular matrix regulation in cardiovascular fibroblasts, as suggested by others (40) . Further investigation of the AT 1A MUT model is needed to delineate the direct physiological effects of AT 1A activation in cardiovascular hypertrophy, fibrosis, and remodeling, independent of hypertension and other factors such as aldosterone.
In conclusion, this description of what we believe to be the first animal model expressing a gain-of-function mutation of AT 1A in a physiological context may provide new insight into the pathophysiology and therapy of human hypertension. Our findings suggest that such genetic defects in humans, if they exist, contribute to high aldosterone-low-renin forms of hypertension. The prevalence of these forms of hypertension, as assessed by aldosterone/renin ratio measurements, is high (34) . This model also reveals the importance of AT 1 activation in cardiovascular remodeling and therefore sustains the usefulness of RAS inhibition in these disorders.
Figure 7
Functional and morphological characterization of AT1AWT and AT1AMUT mouse kidney. Kidney function was evaluated by measuring 24-hour urinary creatinine (A) and Na/K balance (B) for 3 days. All assays were performed in AT1AWT (white bars) and AT1AMUT (black bars) mice fed a normal-sodium diet. (C) Representative kidney histological sections from both mice genotypes stained with Sirius red. Scale bars: 10 μm. (D) Quantitative RT-PCR of collagen αI and PAI1 mRNA in AT1AWT (white bars) and AT1AMUT (black bars) kidneys. *P < 0.05 compared with AT1AWT.
Methods
Generation of AT 1A MUT mice
The targeting AT1A-N111S/Δ329 construct was derived from a 7-kb SpeI(S1)-SacI(A2) genomic fragment contained in a commercial BAC clone (catalog no. FBAC4432; Incyte Genomics Inc.). This 7-kb fragment contains the entire exon 3 of the mouse Agtr1a gene flanked with 3 kb of intron 2 at its 5′ end and 2 kb of noncoding sequence at its 3′ end (Figure 1) . Exon 3 is composed of 5′ untranslated sequence (60 bp), the entire coding sequence, and the 3′ untranslated sequence (830 bp). This 7-kb fragment was digested with SacI, and 4-kb SpeI(S1)-SacI(A1) (fragment 1) and 3-kb SacI(A1)-SacI(A2) (fragment 2) were inserted into a pBlueScript vector (Figure 1A) . The N111S mutation and C-terminal deletion of the AT1A coding sequence were introduced into a 1.5-kb XbaI(X)-SacI(A1) fragment derived from fragment 1 by site-directed mutagenesis using sequential PCR, as previously described (18) . The mutated 1.5-kb XbaI/SacI fragment was reintroduced into fragment 1 in place of the corresponding WT fragment, and fragment 2 was reintroduced into this construction at the SacI site.
The hygromycin resistance gene flanked by loxP sites was inserted into the construct at a Bgl2 site located in the 3′ untranslated sequence. First, a BglII(G1)-BglII(G2) fragment containing the AT1AMUT sequence was deleted and a linker containing unique NruI and NotI sites was inserted into the BglII site. The BglII-BglII fragment was then reintroduced in the correct orientation into the BglII site upstream from the hygromycin cassette ligated between the NruI and NotI sites. This construct was verified by DNA sequencing and restriction mapping.
The final construct was digested with BamHI and KpnI to eliminate plasmid DNA sequences and was electroporated into mouse SV129 ES cells (clone CK35; a gift from C. Kress, Institut Pasteur, Paris, France). Transfected cells were selected with hygromycin 24 hours after electroporation. The DNA of 400 resistant ES cell clones was analyzed by Southern blotting using 2 probes, an internal AT1A sequence probe (probe 1) and an external 3′ fragment probe (probe 2). Digestion of the genomic DNA with SpeI resulted in a 4.8-kb band for the recombinant gene and a 9-kb band for the endogenous WT gene with probe 1. SacI digestion resulted in a 5-kb band for the recombinant gene and a 3-kb band for the endogenous gene recognized by probe 2 (Figure 1, A and B) .
Two appropriate clones were identified by Southern blot (1 positive ES cell clone is shown in Figure 1B ) and PCR (data not shown) and presented a normal karyotype. They were microinjected into C57BL/6 blastocysts, which were then implanted into pseudopregnant mice. Several chimeric animals from 2 different lines were able to transmit the transgene to their progeny. Heterozygous progeny was obtained by successive backcrosses to C57BL/6 females. Homozygous and heterozygous animals were obtained without prenatal or perinatal lethality and have normal fertility. All offspring were genotyped using Southern blot analysis of tail biopsies with the external probe (probe 2) as shown in Figure 1C .
Mice were housed in colony cages with a 12-hour light/12-hour dark cycle in a temperature-controlled environment and had free access to water and a standard diet. Animal studies described here were performed by S. Pharmacological and signaling characterization of the AT 1A MUT mouse AT1A in AT1AWT and AT1AMUT mice was characterized using freshly isolated hepatocytes, the liver being an organ which expresses this receptor subtype exclusively and strongly (4) . The hepatocytes were isolated using the collagenase method as previously described (41). Freshly isolated hepatocytes were then seeded on culture plates for the ERK1/2 phosphorylation assays or were used in suspension for cell membrane extraction in pharmacological experiments.
Saturation and competitive binding assays. Fifty micrograms of purified hepatocyte membranes were incubated with [ 125 I]Ang II with or without various amounts of competitive Ang II ligands, as previously described (42) . Protein phosphorylation analysis. Freshly isolated hepatocytes were seeded on collagen-coated plates at a density of 5 × 10 5 cells in M199 medium as previously described (41) . After cell attachment (2 hours at 37°C, 5% CO2), cells were washed once with M199 medium and incubated for 3 hours at 37°C with fresh serum-free M199 medium for depletion. Then cells were stimulated at 37°C for 5 minutes with Ang II or Ang IV. ERK phosphorylation was analyzed by western blot as previously described (18) using either anti-phospho-ERK1/2 antibody (1/1,000; Cell Signaling Technology) or anti-ERK1/2 antibody (1/1,000; Millipore) and an enhanced chemiluminescence kit (SuperSignal West Pico; Pierce Biotechnology). ChemiGenius 2, GeneSnap (version 6.00), and GeneTools software (version 3.07.03) (Syngene) were used for acquisition and quantification of protein phosphorylation.
For basal STAT1, STAT3, and ERK1/2 phosphorylation in tissues, identical amounts of liver, kidney, and heart protein extracts of AT1AWT and AT1AMUT mice were analyzed using western blot. Anti-phospho and total protein antibodies were from Santa Cruz Biotechnology (p-ERK1/2, and STAT3), Millipore (STAT1 and p-STAT3), Cell Signaling Technology (p-STAT1), and Promega (ERK1/2).
BP measurements
Arterial systolic BP and heart rate were measured by a tail-cuff plethysmography method in trained conscious mice that had been placed in a warming restrainer (Phymep) as previously described (43) . Measurements were repeated for 4 days after training, and approximately 10 consecutive inflation cycles were performed per day. Successful measurements were averaged to determine the perday BP for each mouse. For AT1 blockade assay, candesartan (AstraZeneca) was added to drinking water at 10 mg/kg/d for 25 days. In another set of experiments, losartan (Teva Pharmaceutical Industries Ltd.) was added to drinking water at 30 mg/kg/d for 15 days and then at 150 mg/kg/d for 15 additional days. BP was measured as described above for the last 3 days of each treatment period.
In vivo Ang II reactivity
Acute pressor response to Ang II was measured in anesthetized mice. Flexible plastic catheters were introduced into the femoral artery and in the jugular vein. The arterial catheter was connected to a pressure transducer and a Gould RS 3400 polygraph, and the venous catheter was connected to a syringe for drug injection. The signal was amplified and recorded by a Biopac data acquisition system (MP100; Harvard Apparatus). After at least 30 minutes -necessary to stabilize BP and heart rate -bolus injections of increasing doses of Ang II (0.0001-30 μg/kg) or CGP42112A (0.015-5,000 μg/kg) were administered at 10-minute intervals. Dose response curves were established for the peak of the BP responses, the area under the curve from the time of injection to 8 minutes after injection, and the BP difference between 2 consecutive Ang II injections. Identical experiments were performed in mice after binephrectomy.
Biochemical measurements
Blood was collected by aorta puncture from anesthetized animals. Heparinized blood samples were centrifuged at 3,000 g for 5 minutes, and plasma was collected and frozen.
For urinary determinations, mice were placed individually in metabolic cages for 3 days. Food and water intake and diuresis were measured every day.
Creatinine, urea, protein, Na + , and K + were determined in plasma and urine using an Olympus multiparametric autoanalyzer. Hemoglobin, red blood cell concentration, and hematocrit were determined using a Beckman Coulter MAXM automatic analyzer. Plasma and urine osmolalities were measured by Roebling automatic microosmometer.
Plasma renin concentrations were measured by an indirect enzymatic assay, which determined by RIA the Ang I production of the plasma in the presence of an excess of the substrate angiotensinogen, as previously described (44) . Plasma and urine aldosterone concentrations were determined by RIA assay as previously described (45) . Immunoreactive angio- HR, heart rate; LVEDD/BW, LV end-diastolic diameter normalized to body weight; Ef, ejection fraction; Sa, maximal systolic velocity of the mitral annulus; Spw, maximal systolic velocity of the posterior wall; IVRT, isovolumic relaxation time; Ea, early diastolic mitral annular velocity; Epw, early diastolic motion velocity of the posterior wall; E/Ea, ratio of the maximal blood velocity of early LV inflow to the maximal velocity of early diastolic motion of the mitral annulus. A P < 0.05 compared with AT1AWT.
tensin was measured in plasma by RIA as previously described (46) . This assay measures Ang II, Ang III, and Ang IV together.
Echocardiographic analysis
Echocardiography was performed on lightly anesthetized (1% isoflurane in oxygen; Abbot) 5-and 12-month-old mice, as previously described (47) . Briefly, left ventricle dimensions and pulse-wave tissue Doppler velocity measurements of the posterior wall (Spw) were obtained from the parasternal long-axis view. Left ventricle inflow and outflow pulse-wave Doppler velocities, as well as pulse-wave tissue Doppler of the mitral annulus (Ea and Sa) were obtained from apical 5-chamber view.
Molecular and cellular analyses in Ang II target tissues
Mice were killed and organs (including heart, aorta, kidney, adrenal gland, and liver) were collected. The organs were briefly rinsed with 0.9% saline to remove blood, blotted dry, and weighed. For immunoperoxidase staining and in situ hybridization, organs were fixed in 4% buffered paraformaldehyde and embedded in paraffin. Sections mounted for histology were hybridized with cRNA 35 S-labeled probes as previously reported (48) . Extracellular matrix was stained using Sirius red as described in ref. 49 . Samples were examined by optical microscopy.
Morphometric analysis of arteries. Multiple nonadjacent kidney sections from AT1AWT and AT1AMUT mice were immunohistochemically labeled with an anti-smooth muscle α-actin antibody. For each α-actin-positive artery, the surface of the media (S) and the longest external diameter (L) were measured as previously described (50) . Small arteries with L values between 10 μm and 150 μm were selected. The S/L ratio was used as an index of arterial wall thickness. This ratio was measured for at least 20 different renal arteries for each mouse and was compared between AT1AWT and AT1AMUT mice.
In situ hybridization. Riboprobes were obtained by in vitro transcription of cloned cDNA for human renin, rat angiotensinogen, mouse ACE, rat AT1, and AT2, and a specific probe of the mouse CYP11B2 (nucleotides 825 to 901 of NM009991). After rehydration, microwave heating, and proteinase K digestion, the paraffin-embedded sections were hybridized with 10 4 cpm/μl of 35 S-labeled antisense or sense riboprobe in 30 to 50 μl of hybridization mixture at 50°C for 16 hours. Samples were washed and then digested with RNase A (20 μg/ml) as previously described (48) . The slides were dipped into NTB2 liquid emulsion (Kodak) and stored for 1 to 4 weeks at 4°C in the dark until photographic processing. At the end of the procedure, the slides were examined under a microscope, photographed, and stained with toluidine blue.
Quantitative RT-PCR. Quantitative RT-PCR was used to compare the expression of different genes (Agtr1a, Agtr1b, Agtr2, Nppa, Nppb, Col1a1, and serpine1) in the AT1AWT and AT1AMUT mice using the LightCycler technology (Roche Applied Science). The common reference was the cyclophilin gene. Several tissues were analyzed, including liver, heart, kidney, adrenal, and aorta. Total RNA was extracted from these tissues using TRIzol reagents according to the manufacturer's instructions (Invitrogen), and reverse transcription was performed with the SuperScript II Reverse Transcriptase kit (Invitrogen). All other procedures involving the LightCycler were performed according to manufacturer's instructions (Roche Applied Science).
Statistics
Values are expressed as mean ± SEM. Groups were compared by ANOVA, 2-tailed Student's t test, or a nonparametric test, depending on the nature of the comparison. InStat version 2.01 (GraphPad Software) or StatView (version 5) softwares were used. For tail-cuff BP and heart rate measurements, grouping factors were taken into account by using the multiple comparisons procedure. A P value of 0.05 or less was considered significant.
